Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Skye Bioscience, Inc. before investing.

In this article, we go over a few key elements for understanding Skye Bioscience, Inc.’s stock price such as:

• Skye Bioscience, Inc.’s current stock price and volume
• Why Skye Bioscience, Inc.’s stock price changed recently
• Upgrades and downgrades for SKYE from analysts
• SKYE’s stock price momentum as measured by its relative strength

About Skye Bioscience, Inc. (SKYE)

Before we jump into Skye Bioscience, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.

Want to learn more about Skye Bioscience, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Skye Bioscience, Inc..

Skye Bioscience, Inc.’s Stock Price as of Market Close

As of September 10, 2026, 9:43 AM, CST, Skye Bioscience, Inc.’s stock price was $2.101.

Skye Bioscience, Inc. is down 5.77% from its previous closing price of $2.230.

During the last market session, Skye Bioscience, Inc.’s stock traded between $2.060 and $2.240. Currently, there are approximately 4.96 million shares outstanding for Skye Bioscience, Inc..

Skye Bioscience, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Skye Bioscience, Inc. Stock Price History

Skye Bioscience, Inc.’s (SKYE) price is currently up 25.08% so far this month.

During the month of September, Skye Bioscience, Inc.’s stock price has reached a high of $2.250 and a low of $1.640.

Over the last year, Skye Bioscience, Inc. has hit prices as high as $39.922 and as low as $1.640. Year to date, Skye Bioscience, Inc.’s stock is down 64.96%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Skye Bioscience, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 09, 2026, there were 0 analysts who downgraded Skye Bioscience, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Skye Bioscience, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Skye Bioscience, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Skye Bioscience, Inc. (SKYE) by visiting AAII Stock Evaluator.

Relative Price Strength of Skye Bioscience, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 09, 2026, Skye Bioscience, Inc. has a weighted four-quarter relative price strength of -48.60%, which translates to a Momentum Score of 2 and is considered to be Very Weak.

Want to learn more about how Skye Bioscience, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Skye Bioscience, Inc. Stock Price: Bottom Line

As of September 10, 2026, Skye Bioscience, Inc.’s stock price is $2.101, which is down 5.77% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Skye Bioscience, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.